Philip Haines, MD
Cardiovascular Disease · Philadelphia, PANPI 1043439615
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,903 of the $170,265 with a category attached, or 81.6%. Philips North America LLC accounts for 94.6% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $49,695, 3.5 times the $14,018 reported in 2019. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $818.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$161K
- Edwards Lifesciences$7K
- Abbott$2K
What the payments were for
- Speaking & faculty fees$138,90382%
- Travel & lodging$27,08716%
- Food & beverage$4,2763%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 151 | $161,034 |
| Edwards Lifesciences | 35 | $6,757 |
| Abbott | 22 | $2,474 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (1658) Clinical Educ Ultrasound$94,136
- Educ Ultrasound$48,876
- US Und$12,407
- PASCAL$3,375
- Clin Educ US$2,751
- (1429) C S Enterprise Imaging Informatics$2,000
- EVOQUE$1,839
- Edwards SAPIEN 3 Transcatheter Heart Valve$424
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$213
- Mitra Clip system$142
- MitraClip$139
- TRICLIP$122
How this compares
$170,265 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 84 | $105,899 |
| JardianceEmpagliflozin | 69 | $84,118 |
| XareltoRivaroxaban | 34 | $37,941 |
| Atorvastatin Calcium | 107 | $1,508 |
| Metoprolol Succinate | 77 | $1,129 |
| Losartan Potassium | 64 | $824 |
| Ezetimibe | 23 | $734 |
| Rosuvastatin Calcium | 46 | $713 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $660 |
| Metoprolol Tartrate | 74 | $531 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 25 | $500 |
| Flecainide Acetate | 12 | $500 |
| Amlodipine Besylate | 75 | $499 |
| Torsemide | 15 | $476 |
| Furosemide | 59 | $460 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.